Breaking Finance News

Novavax (NASDAQ:NVAX) has been downgraded from Buy to Neutral in a statement by Citigroup earlier today.

Having a price of $8.34, Novavax (NASDAQ:NVAX) traded 0.36% higher on the day. The last close is up 33.70% relative to the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same time. NVAX has registered a 50-day average of $7.35 and 200-day average of $6.24. Trading volume was was up over the average, with 25,965,663 shares of NVAX changing hands over the typical 5,016,980 shares.

Citigroup has downgraded Novavax(NASDAQ:NVAX) from Buy to Neutral in a statement released 9/16/2016.

Previously on 8/23/2016, Vetr Inc. reported about Novavax(NASDAQ:NVAX) raised the target price from $0.00 to $8.66. At the time, this indicated a possible upside of 0.17%.

Performance Chart:


A total of 8 brokerages have released a report on the stock. Five analysts rate the stock a strong buy, three firms rate the stock a buy, 0 analysts rate the stock a hold, 0 rate the company to underperform, and lastly 0 analystsrate the company as sell with an average target stock price of $15.39

Novavax has a one-year low of $4.08 and a 52 week high of $10.70 . The company’s total market value is currently $0.0.

About Novavax (NASDAQ:NVAX)

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, and including Middle East respiratory syndrome (MERS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *